Research programme: T-cell therapies - Maverick Therapeutics/Takeda

Drug Profile

Research programme: T-cell therapies - Maverick Therapeutics/Takeda

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maverick Therapeutics
  • Developer Maverick Therapeutics; Takeda
  • Class Antibodies; Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 17 Jan 2017 Early research in Cancer in USA (unspecified route)
  • 11 Jan 2017 Maverick Therapeutics and Takeda agree to develop platform for T-cell therapies for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top